Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15120379 | 0.85 | CES2 (0.56) | CES2CES1PTPN1KMT2AMEN1 | |
| SCHEMBL27568385 | 0.80 | CES2 (0.50) | CES2CES1PTPN1KMT2AMEN1 | |
| SCHEMBL27583187 | 0.80 | CES2 (0.55) | CES2CES1PTPN1KMT2AMEN1 | |
| SCHEMBL20169790 | 0.80 | RIPK1 (0.50) | CES2CES1PTPN1KMT2AMEN1 | |
| SCHEMBL7073482 | 0.78 | CES1 (0.58) | CES2CES1PTPN1KMT2AMEN1 | |
| SCHEMBL9631243 | 0.78 | CES2 (0.58) | CES2CES1PTPN1KMT2AMEN1 | |
| SCHEMBL28269833 | 0.77 | SMN1; SMN2 (0.51) | CES2CES1PTPN1KMT2AMEN1 | |
| SCHEMBL12260686 | 0.76 | RAB9A (0.54) | CES2CES1PTPN1KMT2AMEN1 | |
| SCHEMBL43960 | 0.75 | — | — | |
| SCHEMBL27777913 | 0.75 | CES2 (0.65) | CES2CES1PTPN1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230242486-A1 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-06-22 | — | — | US | disclosed |
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-06-22 | — | — | US | disclosed |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-11351264-B2 | PAR2 mimetic peptides and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210393557-A1 | Regulators of the Endoplasmic Reticulum Proteostasis Network | THE SCRIPPS RESEARCH INSTITUTE | 2021-12-23 | — | — | US | disclosed |
| US-11040028-B2 | Penicinotam derivative, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-06-22 | — | — | US | disclosed |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-05-04 | — | — | US | disclosed |
| US-20210107909-A1 | SMALL MOLECULE MODULATORS OF PAR2 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-15 | — | — | US | disclosed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| WO-2005110968-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TERBINAFINE HYDROCHLORIDE | HYDEX CHEMICALS PVT LTD. (IN) | 2005-11-24 | — | — | WO | disclosed |
| EP-1458668-A4 | PROCESS FOR PREPARING TERBINAFINE AND HCI SALT THEREOF | YUHAN CORP LTD (KR) | 2005-02-02 | — | — | EP | disclosed |
| EP-1458668-A1 | PROCESS FOR PREPARING TERBINAFINE AND HCI SALT THEREOF | YUHAN CORPORATION, LTD. (KR) | 2004-09-22 | — | — | EP | disclosed |
| US-6689913-B2 | REDUCTIVE ALKYLATION OF THE REACTION PRODUCT OF AN S-SUBSTITUTED-C-TERT-BUTYL-N-SULFONYLHYDRAZONYLFURAN AND A BASE WITH N-METHYL-1-NAPHTHALENEMETHYLAMINE OR ITS HCL SALT | YUHAN CORPORATION (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030130530-A1 | Process for preparing terbinafine and HCI salt thereof | YUHAN CORPORATION (KR) | 2003-07-10 | — | — | US | disclosed |
| WO-2003055844-A1 | PROCESS FOR PREPARING TERBINAFINE AND HCI SALT THEREOF | YUHAN CORPORATION (KR) | 2003-07-10 | — | — | WO | disclosed |
| CN-1367784-A | Process for preparing substituted propenone derivatives | SHIONOGI & CO (JP) | 2002-09-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | CES2 3614/4885CES1 1784/4885PTPN1 1875/4885 |
| US-11351264-B2 | PAR2 mimetic peptides and uses thereof | F2RL1, F2R, F2RL3 | CES2 3799/4885CES1 2676/4885PTPN1 2551/4885 |
| US-20210107909-A1 | SMALL MOLECULE MODULATORS OF PAR2 AND USES THEREOF | F2RL1, F2R, TBXA2R | CES2 2392/4885CES1 2454/4885PTPN1 2363/4885 |
| US-20230041563-A1 | N-(1,3,4-OXADIAZOL-2-YL)ARYLCARBOXAMIDES OR SALTS THEREOF, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND USES THEREOF | CYP2B6, CBR3, CYP2A6 | CES2 256/4885CES1 490/4885PTPN1 1089/4885 |
| US-20210393557-A1 | Regulators of the Endoplasmic Reticulum Proteostasis Network | XBP1, HSPA5, TFEB | CES2 3500/4885CES1 1227/4885PTPN1 4571/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | CES2 4799/4885CES1 3676/4885PTPN1 911/4885 |
| US-20230242486-A1 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HTR2C, HTR3D, HTR5A | CES2 4022/4885CES1 4312/4885PTPN1 3017/4885 |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | FURIN, PEPD, PIN1 | CES2 461/4885CES1 1210/4885PTPN1 2324/4885 |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | CES2 324/4885CES1 189/4885PTPN1 3650/4885 |
| US-11040028-B2 | Penicinotam derivative, preparation method and use thereof | TPMT, MAPT, TLR4 | CES2 1413/4885CES1 1033/4885PTPN1 241/4885 |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | AR, SHBG, NR5A1 | CES2 4651/4885CES1 2480/4885PTPN1 3255/4885 |
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | CACNA1B, CACNG3, CACNA1C | CES2 570/4885CES1 4554/4885PTPN1 2585/4885 |
| US-20030130530-A1 | Process for preparing terbinafine and HCI salt thereof | TPMT, HNMT, BHMT | CES2 1120/4885CES1 1267/4885PTPN1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.